Latest news with #SimparicaTrio
Yahoo
05-08-2025
- Business
- Yahoo
Zoetis Lifts Outlook As Companion Animal Portfolio Offsets Librela Decline
Animal health firm Zoetis Inc. (NYSE:ZTS) on Tuesday reported a second-quarter 2025 adjusted earnings per share of $1.76, up from $1.56 a year ago, beating the consensus of $1.61. The company reported sales of $2.50 billion, up 4% year over year, beating the consensus of $2.41 billion. On an organic operational basis, revenue for the second quarter of 2025 increased 8% compared with the second quarter of 2024. Revenue in the U.S. segment was $1.4 billion, up 4% and 7% on an organic operational of the company's companion animal products increased 9%, driven primarily by Simparica Trio, the company's flea, tick, and heartworm combination product, as well as its key dermatology portfolio, including Apoquel, Apoquel Chewable, and Cytopoint. Broad-based growth across the remainder of the companion animal portfolio, including vaccines and diagnostics, was partially offset by a decline in the company's monoclonal antibody (mAb) products for osteoarthritis (OA) pain, Librela for dogs, and Solensia for cats. Sales of livestock products declined 21% in the quarter, largely due to the divestiture of the medicated feed additive product portfolio and related assets. On an organic operational basis, sales of livestock products decreased 2% in the quarter due to the timing of supply of ceftiofur products and competition for Draxxin, partially offset by growth across the livestock portfolio, primarily in vaccines. Guidance Zoetis raised its fiscal 2025 revenues guidance from $9.425 billion–$9.575 billion to $9.45 billion-$9.6 billion, compared to the consensus of $9.49 billion. View more earnings on ZTS The animal health company also raised the 2025 adjusted earnings per share from $6.20-$6.30 to $6.30-$6.40, compared to the consensus of $6.23. The company expects adjusted net income of $2.825 billion-$2.875 billion compared to the prior guidance of $2.775 billion-$2.825 billion. The company says the guidance reflects foreign exchange rates and the impact of enacted tariffs. With an eye on future growth, William Blair noted that sentiment around Librela, a key product in Zoetis's portfolio, remains subdued. However, they argue that the product's decline in the U.S. market may not significantly impact overall performance, particularly given the robust performance in the U.S. companion animal segment, which saw strong growth. The momentum in this area appears sufficient to offset the challenges posed by Librela's underperformance. Brandon Vazquez, an analyst at William Blair, commented, 'Investors have been questioning how Zoetis can sustain growth within its long-range plan amid rising competition and struggles with Librela. We think second-quarter results and raised full-year guidance should give incremental confidence that this is not the case.' Zoetis saw its shares initially rise following the release of its stronger-than-expected second-quarter results, alongside an upward revision of its fiscal 2025 EPS and revenue guidance. However, despite the positive report and raised outlook, Zoetis stock has since retraced its earlier gains. Price Action: ZTS stock is trading lower by 2.62% to $147.84 at last check Tuesday. Read Next:Photo by JHVEPhoto via Shutterstock Latest Ratings for ZTS Date Firm Action From To Mar 2022 Citigroup Maintains Neutral Dec 2021 Citigroup Maintains Neutral Nov 2021 Morgan Stanley Initiates Coverage On Overweight View More Analyst Ratings for ZTS View the Latest Analyst Ratings UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? ZOETIS (ZTS): Free Stock Analysis Report This article Zoetis Lifts Outlook As Companion Animal Portfolio Offsets Librela Decline originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Reuters
05-08-2025
- Business
- Reuters
Animal healthcare firm Zoetis raises annual forecast on strong pet product demand
Aug 5 (Reuters) - Zoetis (ZTS.N), opens new tab raised annual forecast and beat second-quarter estimates on Tuesday, driven by strong demand for its medicines and vaccines for pets, sending the animal healthcare company's shares surging about 9% in premarket trading. Analysts remain optimistic about the long-term prospects for the animal health industry, citing a rebound in veterinary clinic visits over the coming years as pet ownership grows and aging animals require chronic care treatments. The New Jersey-based company expects 2025 revenue to be between $9.45 billion and $9.60 billion, compared with its earlier range of $9.43 billion to $9.58 billion. It also raised its forecast for annual adjusted profit per share to between $6.30 and $6.40, from $6.20 to $6.30 projected earlier. Analysts on average were expecting annual revenue of $9.50 billion and earnings of $6.24 per share, according to data compiled by LSEG. Zoetis said its updated forecast reflects foreign exchange rates and the impact of enacted and assumptions on announced tariffs. During the quarter ended June 30, the company's companion animal segment, which includes treatments for dogs and cats, posted an 8% increase in revenue to $1.79 billion. The growth was driven by robust sales of its flea, tick and heartworm combination product Simparica Trio, and its pain and dermatology drugs such as Librela, Solensia, Apoquel and Cytopoint. Zoetis' adjusted earnings of $1.76 per share came in above the consensus estimate of $1.62 per share. Its quarterly revenue rose 4% to $2.46 billion, compared with the estimate of $2.41 billion.
Yahoo
25-06-2025
- Business
- Yahoo
Stifel Downgrades Zoetis (ZTS) Stock, Reduces PT
Zoetis Inc. (NYSE:ZTS) is one of the 10 Worst Aggressive Growth Stocks to Buy According to Short Sellers. On June 18, Stifel analyst Jonathan Block downgraded Zoetis Inc. (NYSE:ZTS)'s stock to 'Hold' from 'Buy,' reducing the price objective to $160 from $165. The firm warned that revenue growth might fall short of Wall Street expectations over the upcoming 2 years as competition intensifies throughout key product categories. While there are longer-term opportunities in oncology and kidney disease, the firm believes that these markets will develop more slowly. A veterinarian administering a vaccine to a herd of cattle in a farm. As per the firm, while Zoetis Inc. (NYSE:ZTS) dealt effectively with competition in the past, this time the competition might prove to be more successful. Stifel's survey identified that there is robust veterinarian interest in Merck's pending Atopic Dermatitis JAK inhibitor and Elanco's CQ – chloroquine. However, Zoetis Inc. (NYSE:ZTS) continues to advance innovation and care for animals throughout the globe. Simparica Trio gained a new label indication in the US to prevent Dipylidium caninum (flea tapeworm) infections by killing Ctenocephalides felis vector fleas in treated dogs. Now, Simparica Trio happens to be the only canine combination parasiticide indicated to prevent flea tapeworm infections, at the source, by killing vector fleas before the transmission. Polen Capital, an investment management company, released its Q4 2024 investor letter. Here is what the fund said: 'Zoetis Inc. (NYSE:ZTS) and Adobe were also notable absolute detractors. Zoetis has been posting excellent growth on the back of its pain and dermatology franchises for quite some time, and its core companion animal business has been firing on all cylinders. Despite this, the stock has come under pressure due to concerns about the growth prospects of Librela, its biologic drug for pain in dogs (as well as Solensia, the sister drug for cats). There has been some concern about the side effects of these drugs, but the data disclosed thus far shows a very low level of adverse events, with drugs that prove highly effective in treating pain. We expect strong growth from these and other drugs currently marketed by Zoetis, with more to come from its prolific pipeline. We used the recent weakness to add to our position.' While we acknowledge the potential of ZTS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ZTS and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None.
